Iovance Biotherapeutics, Inc. Appoints Athena Countouriotis to its Board of Directors and Member of the Board’s Nominating and Corporate Governance Committee and the Compensation Committee
June 11, 2019 at 08:00 am EDT
Share
On June 10, 2019, the board of directors of Iovance Biotherapeutics, Inc. appointed Athena Countouriotis, M.D., as a director and new member of the board, effective June 10, 2019. Upon joining the board, Dr. Countouriotis will also become a member of the board’s Nominating and Corporate Governance Committee and the Compensation Committee. Dr. Countouriotis is the President and Chief Executive Officer of Turning Point Therapeutics, Inc. Prior to joining Turning Point Therapeutics, Inc., Dr. Countouriotis was a Senior Vice President and Chief Medical Officer for Adverum Biotechnologies, Inc. from June 2017 to May 2018, and before that served as Senior Vice President, Chief Medical Officer of Halozyme Therapeutics, Inc. from January 2015 to May 2017.
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Iovance Biotherapeutics, Inc. Appoints Athena Countouriotis to its Board of Directors and Member of the Board’s Nominating and Corporate Governance Committee and the Compensation Committee
IOVANCE BIOTHERAPEUTICS, INC. 
